No holding back Claudin
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
CDH17 becomes flavour of the month
Antibody-drug conjugates hitting this target abound.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
AACR 2025 – an academic reminder about Jemperli
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
AACR 2025 – BioNTech sees its first combo glimmers
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
AACR 2025 – a requiem for Roche's TIGIT
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
Astra stumbles again with Truqap
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
